Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study

被引:19
作者
Alhusain, Faisal [1 ,2 ]
Alromaih, Azam [2 ,3 ]
Alhajress, Ghassan [2 ,3 ]
Alsaghyir, Abdullah [2 ,3 ]
Alqobaisi, Ali [2 ,3 ]
Alaboodi, Talal [2 ,3 ]
Alsalamah, Majid [1 ,2 ,4 ]
机构
[1] Minist Natl Guard Hlth Affairs, Dept Emergency Med, Riyadh 125446439, Saudi Arabia
[2] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia
[3] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, Riyadh, Saudi Arabia
[4] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Publ Hlth & Hlth Informat, Riyadh, Saudi Arabia
关键词
SARS-CoV-2; COVID-19; Hypoxia; Silent hypoxia; Mortality; Risk factors; HYPOXEMIA;
D O I
10.1016/j.jiph.2021.09.007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Patients with COVID-19 usually present with fever and respiratory symptoms such as cough, sputum production, and dyspnea. However, they may suffer from severe hypoxemia without a clinical correlation with the respiratory symptoms, also known as silent or apathetic hypoxia. The aim of the study was to assess the predictors and clinical outcomes of COVID-19 patients without dyspnea. Methods: A single-center retrospective cohort study, based on data extracted from the electronic hospital information system, with COVID-19 patients over a 10-month period in Riyadh, Saudi Arabia. Results: Of the COVID-19 patients presenting at the Emergency Department with a SpO(2) < 90%, 13% had silent hypoxia. The majority of the patients required BiPAP, 34% were intubated and 60% were admitted to an intensive care unit. There was no association between dyspnea and gender, age group, body mass index, or comorbidity. Cough, fever, and chronic cardiac diseases were predictive for dyspnea in a regression analysis. There was no difference in the clinical outcome between patients with silent dyspnea or dyspnea. Age and obesity were significantly associated with a decrease in survival, and an increase in the initial SpO(2) increased survival. Conclusion: Patients with cardiac disease are more likely to present with silent hypoxia. The SpO(2) saturation in COVID-19 may be an independent predictor of survival. Silent hypoxia in COVID-19 patients does not appear to have an association with increase in mortality. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
引用
收藏
页码:1595 / 1599
页数:5
相关论文
共 25 条
[1]   Asymptomatic hypoxia in COVID-19 is associated with poor outcome [J].
Brouqui, Philippe ;
Amrane, Sophie ;
Million, Matthieu ;
Cortaredona, Sebastien ;
Parola, Philippe ;
Lagier, Jean-Christophe ;
Raoult, Didier .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 102 :233-238
[2]   Prevalence and outcome of silent hypoxemia in COVID-19 [J].
Busana, Mattia ;
Gasperetti, Alessio ;
Giosa, Lorenzo ;
Forleo, Giovanni B. ;
Schiavone, Marco ;
Mitacchione, Gianfranco ;
Bonino, Cecilia ;
Villa, Paolo ;
Galli, Massimo ;
Tondo, Claudio ;
Saguner, Ardan ;
Steiger, Peter ;
Curnis, Antonio ;
Dello Russo, Antonio ;
Pugliese, Francesco ;
Mancone, Massimo ;
Marini, John J. ;
Gattinoni, Luciano .
MINERVA ANESTESIOLOGICA, 2021, 87 (03) :325-333
[3]   Silent hypoxia: a frequently overlooked clinical entity in patients with COVID-19 [J].
Chandra, Atanu ;
Chakraborty, Uddalak ;
Pal, Jyotirmoy ;
Karmakar, Parthasarathi .
BMJ CASE REPORTS, 2020, 13 (09)
[4]   The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century [J].
da Costa, Vivaldo Gomes ;
Moreli, Marcos Lazaro ;
Saivish, Marielena Vogel .
ARCHIVES OF VIROLOGY, 2020, 165 (07) :1517-1526
[5]  
Dillon Kate, 2020, Br Paramed J, V5, P59, DOI 10.29045/14784726.2020.09.5.3.59
[6]   Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia [J].
Gokhale, Yojana ;
Mehta, Rakshita ;
Karnik, Nitin ;
Kulkarni, Uday ;
Gokhale, Sushant .
ECLINICALMEDICINE, 2020, 24
[7]   Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy [J].
Grasselli, Giacomo ;
Zangrillo, Alberto ;
Zanella, Alberto ;
Antonelli, Massimo ;
Cabrini, Luca ;
Castelli, Antonio ;
Cereda, Danilo ;
Coluccello, Antonio ;
Foti, Giuseppe ;
Fumagalli, Roberto ;
Iotti, Giorgio ;
Latronico, Nicola ;
Lorini, Luca ;
Merler, Stefano ;
Natalini, Giuseppe ;
Piatti, Alessandra ;
Ranieri, Marco Vito ;
Scandroglio, Anna Mara ;
Storti, Enrico ;
Cecconi, Maurizio ;
Pesenti, Antonio .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (16) :1574-1581
[8]   Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study [J].
Gupta, Rishi K. ;
Marks, Michael ;
Samuels, Thomas H. A. ;
Luintel, Akish ;
Rampling, Tommy ;
Chowdhury, Humayra ;
Quartagno, Matteo ;
Nair, Arjun ;
Lipman, Marc ;
Abubakar, Ibrahim ;
van Smeden, Maarten ;
Wong, Wai Keong ;
Williams, Bryan ;
Noursadeghi, Mahdad .
EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (06)
[9]   COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far [J].
Khan, Mujeeb ;
Adil, Syed F. ;
Alkhathlan, Hamad Z. ;
Tahir, Muhammad N. ;
Saif, Sadia ;
Khan, Merajuddin ;
Khan, Shams T. .
MOLECULES, 2021, 26 (01)
[10]   Extra-respiratory manifestations of COVID-19 [J].
Lai, Chih-Cheng ;
Ko, Wen-Chien ;
Lee, Ping-Ing ;
Jean, Shio-Shin ;
Hsueh, Po-Ren .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (02)